Pfizer Inc

PFE
Healthcare · Drug Manufacturers - General
25.25
+0.58 (+2.35%)
USD · NYSE

Company Information

Company Name
Pfizer Inc
Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NYSE
ISIN: US7170811035
CIK: 0000078003
CUSIP: 717081103
Currency: USD
Full Time Employees: 75,000
Phone: 212 733 2323
Fiscal Year End: December
IPO Date: Jun 22, 1942
Description:

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Address:

66 Hudson Boulevard East, New York, NY, United States, 10001-2192

People

Directors & Officers

Name Title Year Born
Dr. Albert Bourla D.V.M., Ph.D. Chairman of the Board & CEO 1962
Mr. David M. Denton Executive VP & CFO 1965
Dr. Chris Boshoff FMedSci, M.D., Ph.D. Chief Scientific Officer and President of Research & Development 1964
Mr. Douglas M. Lankler Executive VP & Chief Legal Officer 1966
Mr. Aamir Malik Executive VP & Chief U.S. Commercial Officer 1976
Ms. Jennifer B. Damico Senior VP, Controller & Principal Accounting Officer 1969
Mr. Dennis P. Hancock Executive VP & Chief Information Officer NA
Ms. Francesca M. DeMartino Chief Investor Relations Officer NA
Ms. Payal Sahni Becher Chief People Experience Officer & Executive VP 1975
Dr. Michael S. Vincent M.D., Ph.D. Senior VP and Chief Scientific Officer of Inflammation & Immunology NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Mar 13, 2026 Gilbert Ray Cisneros, Jr. N/A Sale N/A $26.60 N/A
Feb 10, 2026 Gilbert Ray Cisneros, Jr. N/A Purchase N/A $27.61 N/A
Jan 22, 2026 Ro Khanna N/A Sale N/A $26.09 N/A
Dec 31, 2025 J. French Hill N/A Sale N/A $24.90 N/A
Dec 19, 2025 Gilbert Ray Cisneros, Jr. N/A Sale N/A $25.19 N/A
Nov 18, 2025 Gilbert Ray Cisneros, Jr. N/A Purchase N/A $25.45 N/A
Sep 15, 2025 Ro Khanna N/A Sale N/A $23.98 N/A
Sep 05, 2025 Ro Khanna N/A Sale N/A $24.86 N/A
Aug 05, 2025 Gilbert Ray Cisneros, Jr. N/A Sale N/A $24.69 N/A
Aug 04, 2025 Ro Khanna N/A Purchase N/A $23.56 N/A
Aug 04, 2025 Lisa C. McClain N/A Sale N/A $23.56 N/A
Jul 16, 2025 Lisa C. McClain N/A Purchase N/A $24.59 N/A
Jul 01, 2025 Ro Khanna N/A Purchase N/A $25.03 N/A
Jun 20, 2025 Ro Khanna N/A Purchase N/A $23.97 N/A
Jun 03, 2025 Josh Gottheimer N/A Sale N/A $23.37 N/A
Jun 03, 2025 Ron Wyden N/A Sale N/A $23.37 N/A
May 30, 2025 Gilbert Ray Cisneros, Jr. N/A Purchase N/A $23.46 N/A
May 28, 2025 Ro Khanna N/A Purchase N/A $23.18 N/A
May 19, 2025 Ro Khanna N/A Purchase N/A $23.01 N/A
May 15, 2025 Robert Bresnahan, Jr. N/A Purchase N/A $22.57 N/A

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Vanguard Group Inc 541.35M Dec 31, 2025 9.50% $0.20 1.32%
BlackRock Inc 498.26M Mar 31, 2026 8.74% $0.24 1.05%
Vanguard Capital Management, LLC 369.43M Mar 31, 2026 6.48% $0.26 0.00%
State Street Corp 301.59M Mar 31, 2026 5.29% $0.29 0.38%
Geode Capital Management, LLC 133.56M Mar 31, 2026 2.34% $0.23 2.59%
Vanguard Portfolio Management, LLC 116.73M Mar 31, 2026 2.05% $0.17 0.00%
Fisher Asset Management, LLC 104.96M Mar 31, 2026 1.84% $1.00 102.04%
Morgan Stanley - Brokerage Accounts 92.69M Mar 31, 2026 1.63% $0.16 4.01%
NORGES BANK 73.53M Dec 31, 2025 1.29% $0.20 -21.48%
Northern Trust Corp 62.03M Mar 31, 2026 1.09% $0.23 -1.94%
Massachusetts Financial Services Company 56.91M Mar 31, 2026 1.00% $0.54 1.86%
State Farm Mutual Automobile Ins Co 54.51M Mar 31, 2026 0.96% $1.21 0.00%
Bank of New York Mellon Corp 53.88M Mar 31, 2026 0.95% $0.28 11.06%
Charles Schwab Investment Management Inc 51.89M Mar 31, 2026 0.91% $0.22 2.67%
Wellington Management Company LLP 49.92M Mar 31, 2026 0.88% $0.26 -4.18%
The Goldman Sachs Group Inc 47.11M Mar 31, 2026 0.83% $0.15 17.60%
Bank of America Corp 46.55M Mar 31, 2026 0.82% $0.10 -4.58%
Legal & General Group PLC 43.51M Mar 31, 2026 0.76% $0.28 1.50%
Amundi 40.83M Mar 31, 2026 0.72% $0.31 -13.25%
Dimensional Fund Advisors, Inc. 36.42M Mar 31, 2026 0.64% $0.21 0.81%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 180.98M 3.18% ▼ 0.01% Jun 30, 2026
2 Vanguard 500 Index Investor 148.06M 2.60% ▼ 0.54% Jun 30, 2026
3 iShares Core S&P 500 ETF 78.61M 1.38% ▲ 0.32% Jun 30, 2026
4 Fidelity 500 Index 72.76M 1.28% ▼ 0.14% May 31, 2026
5 State Street® SPDR® S&P 500® ETF 68.87M 1.21% ▼ 1.29% Jun 30, 2026
6 Vanguard Value Index Inv 54.19M 0.95% ▲ 2.15% Jun 30, 2026
7 State Street®HlthCrSelSectSPDR®ETF 40.41M 0.71% ▲ 0.79% Jun 30, 2026
8 Vanguard Institutional Index I 30.92M 0.54% ▼ 0.64% Jun 30, 2026
9 State St S&P 500® Idx SL Cl I 30.28M 0.53% ▼ 0.70% Jun 30, 2026
10 Vanguard Institutional 500 Index Trust 25.76M 0.45% ▲ 0.13% Jun 30, 2026

Financial Highlights

Market Cap: $139.86B
EBITDA: $25.46B
P/E Ratio: $18.83
PEG Ratio: $2.90
Book Value: $15.81
Dividend/Share: $1.72
Dividend Yield: 7.01%
Earnings/Share: $1.31
Profit Margin: 11.83%
Operating Margin: 31.62%
ROA (TTM): 5.69%
ROE (TTM): 8.31%
Revenue (TTM): $63.32B
Revenue/Share (TTM): $11.13
Earnings Growth (YOY): -10.10%
Revenue Growth (YOY): 5.40%

Valuation Metrics

Enterprise Value: $191.26B
Trailing P/E: 18.83
Forward P/E: 8.40

Shares Statistics

Shares Outstanding: 5.70B
Shares Float: 5.69B
% Insiders: 9.50%
% Institutions: 6,954.90%
Short % Float: 2.87%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$62.58B
Cost of Goods Sold
adjust
$-18.57B
Gross Profit
subtotal
$44.01B
SG&A
adjust
$-13.64B
R&D
adjust
$-11.98B
Other Operating Expense
adjust
$-2.96B
Operating Income
subtotal
$15.44B
Other / Non-Operating Items
adjust
$-7.67B
Net Income
subtotal
$7.77B

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about PFE!